Vitaccess

We’re delighted to share the launch of the Vitaccess Real CIDP Registry, alongside the enrolment of the first patient.

There remains a significant insight gap in rare disease, particularly between what clinical trials capture and what patients and caregivers experience over time.

In chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), that gap is especially pronounced. CIDP is a rare autoimmune disorder that leads to progressive weakness, sensory loss, and impaired mobility.

The registry is a collaboratively designed, patient-centred research platform, developed in partnership with advocacy groups, clinicians, and academic partners. It aims to generate longitudinal, real-world evidence integrating patient-reported outcomes, clinical data, and medical records within a single, secure framework, with the goal of improving the standard of care for patients and caregivers living with CIDP.

The registry is guided by a leading Scientific Advisory Board that includes Professor Yusuf Rajabally, Professor Ali Habib, and Professor Mark Stettner, alongside patient advocacy representatives Nancy Di Salvo and Rich Collins.

You can read more about the registry on our website here:

We’re looking forward to attending the Myasthenia Gravis Foundation of America, Inc. (MGFA) National Patient Conference on 12-14 April.

Our Founder & CEO, Mark Larkin, and Head of Commercial, Anna Richards, will be in attendance, connecting with patients, caregivers, and the wider community.

We will be presenting a session on the MGFA & Vitaccess Patient Registry titled ‘Harnessing Patient Data for Better MG Care’ on Monday 13 April, 1:40pm ET.

This session reflects our ongoing commitment to building patient-centred, real-world evidence through collaboratively designed registries.

If you’re attending, we’d be delighted to connect.

You can find more detail on the agenda here: https://bit.ly/4s42HRc